In a significant development within the opioid litigation landscape, McKinsey & Company has intensified its legal proceedings against Endo International Plc by seeking internal records related to opioid sales. This move is a strategic effort to bolster its defense in ongoing lawsuits that challenge the consultancy’s role in advising opioid manufacturers.
The request for records was revealed in a recent court filing, marking a critical phase in McKinsey’s endeavor to clarify its involvement in the opioid crisis, which has resulted in widespread litigation across the U.S. The firm has been under scrutiny for its advisory services to pharmaceutical companies, including Purdue Pharma, the maker of OxyContin. By securing Endo’s internal documents, McKinsey aims to furnish evidence that could potentially distance itself from direct liability or diminish its perceived contribution to the opioid epidemic.
Endo International, known for producing opioid medications, has been embroiled in legal battles over its marketing practices and alleged role in fostering addiction. The request for documentation from McKinsey highlights the consultancy’s proactive stance in sifting through tangible evidence that may demonstrate the scope and nature of its consultancy work with Endo. Further insights into this legal strategy can be found in Bloomberg Law.
Meanwhile, McKinsey’s legal challenges are part of a broader trend of financial settlements and court cases that involve numerous stakeholders, from pharmaceutical companies to distributors and consultants. Earlier in the year, McKinsey reached a $573 million settlement with 47 states, the District of Columbia, and five territories over its opioid work, without admitting wrongdoing, as detailed by Reuters.
This pursuit of internal documents from Endo could potentially set a precedent, as McKinsey seeks to substantiate its claims and provide a clearer narrative concerning its consultancy roles. The outcome of this request may not only impact McKinsey’s legal standing but could also influence how consultancy services are scrutinized in future corporate litigation affairs involving public health crises.